Christopher Ryan Sullivan Sells 10,185 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Sullivan sold 10,185 shares of the stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $17.62, for a total transaction of $179,459.70. Following the transaction, the chief financial officer owned 39,900 shares in the company, valued at $703,038. This trade represents a 20.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Avalo Therapeutics Stock Down 6.0%

Shares of AVTX traded down $1.03 during midday trading on Friday, hitting $16.15. The company had a trading volume of 2,525,345 shares, compared to its average volume of 1,145,632. The company’s 50 day moving average price is $19.13 and its 200 day moving average price is $17.06. The stock has a market cap of $866.12 million, a price-to-earnings ratio of -3.70 and a beta of 0.78. Avalo Therapeutics, Inc. has a 52 week low of $9.54 and a 52 week high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). Equities analysts anticipate that Avalo Therapeutics, Inc. will post -2.69 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on AVTX. Mizuho upped their price target on Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. BTIG Research reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Avalo Therapeutics in a report on Tuesday, June 16th. HC Wainwright lowered their target price on shares of Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Wedbush dropped their target price on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Finally, Weiss Ratings upgraded shares of Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $45.10.

Institutional Trading of Avalo Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its holdings in shares of Avalo Therapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after purchasing an additional 2,648 shares during the last quarter. Nantahala Capital Management LLC grew its stake in Avalo Therapeutics by 10.6% during the 2nd quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock worth $4,965,000 after buying an additional 95,000 shares during the last quarter. Bank of America Corp DE increased its position in Avalo Therapeutics by 7,066.8% in the second quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock worth $2,029,000 after buying an additional 400,898 shares during the period. Boothbay Fund Management LLC acquired a new stake in Avalo Therapeutics in the second quarter worth $56,000. Finally, Vanguard Group Inc. lifted its stake in Avalo Therapeutics by 314.9% in the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock valued at $8,803,000 after buying an additional 525,696 shares during the last quarter. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.